Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Frequently Asked Questions About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
How can investors learn more about Neurocrine?
Investors can learn more about Neurocrine Biosciences by visiting the company's official website, accessing press releases, financial reports, and investor presentations. Additionally, Nasdaq provides trading information and updates concerning its stock performance, making it easier for investors to stay informed.
How does Neurocrine approach research and development?
Neurocrine utilizes a robust approach to research and development by combining innovative science with clinical expertise. The company invests in early-stage research as well as late-stage clinical trials, employing rigorous methodologies to ensure the efficacy and safety of its compounds before they reach the market.
How does Neurocrine contribute to the community?
Neurocrine Biosciences is committed to giving back to the community through various initiatives, including patient support programs, educational initiatives, and collaborations with healthcare organizations. The company strives to raise awareness about neurological and endocrine disorders while also supporting research and community health initiatives.
How does Neurocrine ensure drug safety?
Neurocrine follows stringent regulatory guidelines throughout the drug development process to ensure safety and efficacy. This includes conducting rigorous preclinical research, extensive clinical trials, and ongoing surveillance post-marketing. The company adheres to industry best practices to monitor potential side effects and ensure that its treatments meet the highest safety standards.
How does Neurocrine handle intellectual property?
Neurocrine is committed to protecting its intellectual property, which is vital for safeguarding its research innovations and maintaining competitive advantage in the biopharmaceutical industry. The company actively pursues patents and trademarks to secure its discoveries and ensure a strong foundation for its future developments.
What are Neurocrine's future goals?
Neurocrine Biosciences aims to expand its pipeline of innovative therapies and continue addressing unmet medical needs in the neurological and endocrine fields. Future goals include advancing existing clinical trials, seeking new drug approvals, and forming strategic partnerships to enhance research and improve patient care.
What are some key products developed by Neurocrine?
Neurocrine has developed several important products, including Ingrezza (valbenazine) for the treatment of tardive dyskinesia and Orilissa (elagolix) for endometriosis. These products reflect the company’s focus on addressing complex neurological and endocrine conditions and its commitment to improving the lives of patients.
What clinical trials is Neurocrine currently conducting?
Neurocrine is actively engaged in multiple clinical trials across its pipeline of drug candidates. These trials focus on various conditions within its therapeutic areas including tardive dyskinesia, endometriosis, and other neurological conditions. The studies are designed to rigorously test the safety and efficacy of potential new therapies.
What does Neurocrine Biosciences, Inc. do?
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company specializes in research and development for conditions such as movement disorders, psychiatric disorders, and hormone-related diseases. By leveraging advanced science and clinical expertise, Neurocrine aims to address significant unmet medical needs.
What is Neurocrine's financial performance like?
Neurocrine Biosciences has shown a strong financial performance, reflecting its successful product launches and strategic management. The company’s revenue has been supported by the sales of its approved drugs, and it is positioned for potential growth as it advances additional therapies through clinical development.
What is Neurocrine's mission statement?
Neurocrine Biosciences' mission is to develop innovative medicines that transform the lives of patients with neurological and endocrine diseases. The company is dedicated to addressing unmet medical needs and improving outcomes through scientific advancement and compassionate care.
What is the significance of Nasdaq: NBIX?
Nasdaq: NBIX is the stock ticker symbol for Neurocrine Biosciences, Inc. on the Nasdaq stock exchange. This designation allows investors to trade the company's stock, providing it with capital for ongoing research and development activities, while also providing transparency and regulatory oversight as a publicly traded entity.
What partnerships does Neurocrine have?
Neurocrine has established strategic partnerships with various academic institutions, pharmaceutical companies, and research organizations. These collaborations enhance its research capabilities and broaden its therapeutic exploration, ultimately advancing the development of new treatments and improving patient outcomes.
What recent achievements has Neurocrine made?
In recent years, Neurocrine has celebrated several achievements, including the successful launch of new medications, progression of its clinical trials, and strategic partnerships that enhance its pipeline of therapies. These milestones demonstrate the company's commitment to innovation and patient care in its targeted therapeutic areas.
What role does technology play at Neurocrine?
Technology plays a crucial role at Neurocrine, particularly in research, drug discovery, and data analysis. The company employs state-of-the-art technology platforms to propel its research efforts forward, enhance operational efficiency, and improve the accuracy of clinical data, fostering a culture of innovation.
What therapeutic areas does Neurocrine focus on?
Neurocrine focuses primarily on neurological and endocrine therapeutic areas. This includes conditions such as movement disorders, endocrine disorders, and certain psychiatric conditions. The company's research is aimed at developing drugs that can make a meaningful impact in these critical areas, which often involve complex patient needs.
When was Neurocrine Biosciences founded?
Neurocrine Biosciences was founded in 1992. The company has evolved significantly since its inception and has established itself as a leader in the development of treatments for various neurological and endocrine disorders. This long-standing presence in the biopharmaceutical industry underscores its commitment to innovation and patient care.
Where is Neurocrine Biosciences headquartered?
Neurocrine Biosciences is headquartered in San Diego, California. The location allows the company to tap into a rich ecosystem of biotechnology and life sciences, facilitating collaboration with other innovators and researchers in the field and positioning itself strategically within the industry.
Who are the key executives at Neurocrine Biosciences?
The leadership team at Neurocrine Biosciences includes experienced professionals from various fields within the pharmaceutical and biotechnology industries. Executives include the CEO, who drives the strategic vision of the company, and other key figures overseeing R&D, finance, and business development, each contributing their expertise to the company's growth and direction.
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 95.65
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 4:00 pm EDT on April 4th, 2025
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 9.51B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 99.40M shares outstanding.